News
Archive: November 2025
Global Phase 3 Clinical Trial Contract Win
17 November 2025 IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience precision medicine and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced that it has signed a new commercial contract with a global pharmaceutical company to provide imaging services for a worldwide Phase 3 clinical trial in Huntington’s Disease (HD). The total contract value is over £3.5m over four years.
Capital Markets Day Presentation and Video 2025
Capital Markets Day Presentation and Video 03 November 2025 IXICO plc (AIM: IXI) – London, UK.